LT2515870T - Topinė akių peptidų kompozicija - Google Patents
Topinė akių peptidų kompozicijaInfo
- Publication number
- LT2515870T LT2515870T LTEP10810911.7T LT10810911T LT2515870T LT 2515870 T LT2515870 T LT 2515870T LT 10810911 T LT10810911 T LT 10810911T LT 2515870 T LT2515870 T LT 2515870T
- Authority
- LT
- Lithuania
- Prior art keywords
- topical ophthalmic
- peptide formulation
- ophthalmic peptide
- formulation
- topical
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200931242A ES2362604B1 (es) | 2009-12-22 | 2009-12-22 | Formulación tópica oftálmica de péptidos. |
| PCT/EP2010/007737 WO2011076368A2 (en) | 2009-12-22 | 2010-12-17 | Topical ophthalmic peptide formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2515870T true LT2515870T (lt) | 2016-10-10 |
Family
ID=43928893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP10810911.7T LT2515870T (lt) | 2009-12-22 | 2010-12-17 | Topinė akių peptidų kompozicija |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9216208B2 (lt) |
| EP (1) | EP2515870B1 (lt) |
| JP (1) | JP5920928B2 (lt) |
| KR (1) | KR101657737B1 (lt) |
| CN (1) | CN102753153B (lt) |
| AR (1) | AR079683A1 (lt) |
| AU (1) | AU2010335595B2 (lt) |
| BR (1) | BR112012015386B8 (lt) |
| CA (1) | CA2785104C (lt) |
| CL (1) | CL2012001737A1 (lt) |
| CO (1) | CO6592047A2 (lt) |
| CY (1) | CY1117854T1 (lt) |
| DK (1) | DK2515870T3 (lt) |
| ES (2) | ES2362604B1 (lt) |
| HR (1) | HRP20160954T1 (lt) |
| HU (1) | HUE028193T2 (lt) |
| IL (1) | IL220584A (lt) |
| LT (1) | LT2515870T (lt) |
| MX (1) | MX338323B (lt) |
| MY (1) | MY178169A (lt) |
| NZ (1) | NZ600627A (lt) |
| PH (1) | PH12012501271A1 (lt) |
| PL (1) | PL2515870T3 (lt) |
| PT (1) | PT2515870T (lt) |
| RS (1) | RS54953B1 (lt) |
| RU (1) | RU2561585C2 (lt) |
| SG (1) | SG181727A1 (lt) |
| SI (1) | SI2515870T1 (lt) |
| SM (1) | SMT201600277B (lt) |
| TW (1) | TWI548416B (lt) |
| UA (1) | UA108484C2 (lt) |
| UY (1) | UY33153A (lt) |
| WO (1) | WO2011076368A2 (lt) |
| ZA (1) | ZA201204522B (lt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6368722B2 (ja) | 2013-03-01 | 2018-08-01 | フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド |
| GB201516066D0 (en) * | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
| CN106822182A (zh) * | 2016-12-27 | 2017-06-13 | 广州姿生生物科技有限公司 | 一种细胞提取物及其用途 |
| CN110167516B (zh) | 2017-01-31 | 2022-08-30 | 金伯利-克拉克环球有限公司 | 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法 |
| KR20200003923A (ko) * | 2017-05-15 | 2020-01-10 | 썬 파마슈티컬 인더스트리스 리미티드 | 옥트레오티드 주사제 |
| TW202133845A (zh) * | 2019-11-21 | 2021-09-16 | 韓商三進製藥股份有限公司 | 用於預防或治療眼部疾病之眼用組合物 |
| KR102741835B1 (ko) * | 2022-03-11 | 2024-12-12 | 한국한의약진흥원 | 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물 |
| CN120131956A (zh) * | 2023-12-11 | 2025-06-13 | 中山大学中山眼科中心 | 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182258A (en) | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
| CN1244794A (zh) | 1997-11-06 | 2000-02-16 | 奥尔班公司 | 用于药物释放的稳定的干燥药物组合物及其制备方法 |
| CA2263042A1 (en) * | 1999-02-25 | 2000-08-25 | Robert W.A. Kuijpers | Treatment of edema |
| EP1040837A3 (en) * | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
| AU2001283957A1 (en) | 2000-07-27 | 2002-02-13 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
| TWI260228B (en) * | 2002-12-31 | 2006-08-21 | Ind Tech Res Inst | Delivery carrier of presenting cell of somatostatin receptor |
| US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| JP5165239B2 (ja) * | 2003-07-15 | 2013-03-21 | ピーアール ファーマシューティカルズ, インコーポレイテッド | 制御放出処方物の調製のための方法 |
| US20070082841A1 (en) * | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| CA2698666A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| ES2528409T3 (es) * | 2007-10-24 | 2015-02-10 | Camurus Ab | Formulaciones de liberación controlada |
-
2009
- 2009-12-22 ES ES200931242A patent/ES2362604B1/es not_active Expired - Fee Related
-
2010
- 2010-12-17 PH PH1/2012/501271A patent/PH12012501271A1/en unknown
- 2010-12-17 WO PCT/EP2010/007737 patent/WO2011076368A2/en not_active Ceased
- 2010-12-17 SG SG2012044178A patent/SG181727A1/en unknown
- 2010-12-17 HR HRP20160954TT patent/HRP20160954T1/hr unknown
- 2010-12-17 DK DK10810911.7T patent/DK2515870T3/en active
- 2010-12-17 UA UAA201207318A patent/UA108484C2/ru unknown
- 2010-12-17 RS RS20160598A patent/RS54953B1/sr unknown
- 2010-12-17 PT PT108109117T patent/PT2515870T/pt unknown
- 2010-12-17 RU RU2012126028/15A patent/RU2561585C2/ru active
- 2010-12-17 SI SI201031249A patent/SI2515870T1/sl unknown
- 2010-12-17 MY MYPI2012002758A patent/MY178169A/en unknown
- 2010-12-17 BR BR112012015386A patent/BR112012015386B8/pt active IP Right Grant
- 2010-12-17 NZ NZ600627A patent/NZ600627A/en unknown
- 2010-12-17 MX MX2012007282A patent/MX338323B/es active IP Right Grant
- 2010-12-17 EP EP10810911.7A patent/EP2515870B1/en active Active
- 2010-12-17 JP JP2012545144A patent/JP5920928B2/ja active Active
- 2010-12-17 KR KR1020127019503A patent/KR101657737B1/ko active Active
- 2010-12-17 CA CA2785104A patent/CA2785104C/en active Active
- 2010-12-17 HU HUE10810911A patent/HUE028193T2/en unknown
- 2010-12-17 AU AU2010335595A patent/AU2010335595B2/en active Active
- 2010-12-17 PL PL10810911.7T patent/PL2515870T3/pl unknown
- 2010-12-17 US US13/518,617 patent/US9216208B2/en active Active
- 2010-12-17 LT LTEP10810911.7T patent/LT2515870T/lt unknown
- 2010-12-17 ES ES10810911.7T patent/ES2587828T3/es active Active
- 2010-12-17 CN CN201080063430.8A patent/CN102753153B/zh active Active
- 2010-12-21 AR ARP100104857A patent/AR079683A1/es not_active Application Discontinuation
- 2010-12-22 UY UY0001033153A patent/UY33153A/es unknown
- 2010-12-22 TW TW099145240A patent/TWI548416B/zh active
-
2012
- 2012-06-19 ZA ZA2012/04522A patent/ZA201204522B/en unknown
- 2012-06-21 IL IL220584A patent/IL220584A/en active IP Right Grant
- 2012-06-22 CL CL2012001737A patent/CL2012001737A1/es unknown
- 2012-07-10 CO CO12115592A patent/CO6592047A2/es unknown
-
2016
- 2016-07-22 CY CY20161100721T patent/CY1117854T1/el unknown
- 2016-08-16 SM SM201600277T patent/SMT201600277B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245328B (en) | A pharmaceutical preparation containing carbatocin | |
| ZA201304514B (en) | Topical localized isoxazoline formulation | |
| ZA201200719B (en) | Pharmaceutical formulation | |
| EP2659911A4 (en) | AQUEOUS OPHTHALMIC COMPOSITION | |
| EP2566487A4 (en) | OPHTHALMIC COMPOSITION | |
| PL2496596T3 (pl) | Peptydy terapeutyczne | |
| ZA201305591B (en) | Fluorocarbon-linked peptide formulation | |
| GB0921686D0 (en) | Topical formulation | |
| GB0912239D0 (en) | Cosmetic formulation | |
| EP2605786A4 (en) | THERAPEUTIC PEPTIDES | |
| IL220584A0 (en) | Topical ophthalmic peptide formulation | |
| GB0907003D0 (en) | Formulation | |
| WO2010114629A9 (en) | Formulation | |
| GB0908515D0 (en) | Peptide | |
| ZA201203722B (en) | Peptide | |
| GB0911213D0 (en) | Formulation | |
| GB0907410D0 (en) | Formulation | |
| GB201018773D0 (en) | Topical pharmaceutical formulation | |
| GB0918285D0 (en) | Topical formulations | |
| GB0918286D0 (en) | Topical formulations | |
| GB201013824D0 (en) | Ophthalmic formulations | |
| GB201007358D0 (en) | Conjugated protein C | |
| GB0906291D0 (en) | Formulation | |
| GB0902472D0 (en) | Formulation | |
| GB0914356D0 (en) | Ophthalmic formulations |